News articles about AxoGen (NASDAQ:AXGN) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AxoGen earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news articles about the medical equipment provider an impact score of 46.9977338689079 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- AxoGen (AXGN) Receives New Coverage from Analysts at Leerink Swann (americanbankingnews.com)
- AxoGen (AXGN) Lowered to Hold at BidaskClub (americanbankingnews.com)
- Analysts See $0.17 EPS for Timbercreek Financial (TF); Pura Vida Investments Has Decreased Its Axogen (AXGN) Stake (mtastar.com)
- Ubs Oconnor Has Increased Ctrip Co (CTRP) Stake; Last Week AxoGen, Inc. (AXGN) Coverage (mtastar.com)
- Global Nerve Repair and Regeneration Market 2018 Top Players – Axogen, Baxter, Boston Scientific, Livanova, Integra … (healthcaretrends24.com)
AXGN opened at $37.95 on Monday. The firm has a market capitalization of $1,311.56, a P/E ratio of -122.42 and a beta of 0.01. AxoGen has a 12 month low of $11.30 and a 12 month high of $40.95. The company has a current ratio of 4.07, a quick ratio of 3.53 and a debt-to-equity ratio of 0.79.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, February 28th. The medical equipment provider reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. The business had revenue of $16.97 million for the quarter, compared to analysts’ expectations of $16.38 million. AxoGen had a negative net margin of 17.29% and a negative return on equity of 70.63%. The firm’s revenue was up 48.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.10) EPS. equities analysts forecast that AxoGen will post -0.3 EPS for the current year.
AXGN has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $37.00 price target on shares of AxoGen and gave the stock a “buy” rating in a research report on Monday, January 8th. BidaskClub cut shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 11th. Lake Street Capital set a $38.00 price target on shares of AxoGen and gave the stock a “buy” rating in a research report on Friday, March 2nd. JMP Securities lifted their price target on shares of AxoGen from $27.00 to $34.00 and gave the stock a “market outperform” rating in a research report on Thursday, March 1st. Finally, Jefferies Group lifted their price target on shares of AxoGen to $45.00 and gave the stock a “buy” rating in a research report on Monday, March 19th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $33.14.
In related news, CFO Jamie Mark Grooms sold 95,712 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $26.84, for a total value of $2,568,910.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 169,407 shares of company stock worth $4,593,013 over the last ninety days. 7.86% of the stock is currently owned by insiders.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.